Breakout Stocks of Week 27 @ GER
NASDAQ was up last week (week 26) by 0.244% ending at 17,732.60 points after gaining 43.24 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are QIAGEN N.V. GER:QIA. This stock has had a buy signal since Jun 28, 2024 when the price was 38.55€ , but have so far fallen 0% to 38.55€. Some other companies are on our watchlist to, among these are Grand City Properties S.A. GER:GYC Vonovia SE GER:VNA Commerzbank AG GER:CBK and Fresenius Medical Care AG & Co. KGaA GER:FME which all got a breakout pattern emerging.
| Date | Company | Price | Change |
|---|---|---|---|
| Qiagen N.v. | 38.55€ | 37.81€ ( 2nd Jul 2024 ) | -1.92% |
| Grand City Properties S.a. | 10.80€ | 10.81€ ( 2nd Jul 2024 ) | 0.0926% |
| Vonovia Se | 26.55€ | 26.24€ ( 2nd Jul 2024 ) | -1.17% |
| Commerzbank Ag | 14.19€ | 14.52€ ( 2nd Jul 2024 ) | 2.36% |
| Fresenius Medical Care Ag & Co. Kgaa | 35.76€ | 35.69€ ( 2nd Jul 2024 ) | -0.196% |
The QIAGEN N.V. stock price gained 0.508% on the last trading day (Friday, 28th Jun 2024), rising from 38.36€ to 38.55€. During the last trading day the stock fluctuated 1.74% from a day low at 38.20€ to a day high of 38.87€. The price has risen in 7 of the last 10 days but is still down by -2.9% for this period. Volume fell on the last day by -133 thousand shares and in total, 610 thousand shares were bought and sold for approximately 23.51€ million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.
About QIAGEN N.V.:
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
The Grand City Properties S.A. stock price gained 1.98% on the last trading day (Friday, 28th Jun 2024), rising from 10.59€ to 10.80€. During the last trading day the stock fluctuated 2.18% from a day low at 10.57€ to a day high of 10.80€. The price has risen in 6 of the last 10 days and is up by 1.6% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 106 thousand more shares were traded than the day before. In total, 218 thousand shares were bought and sold for approximately 2.35€ million.
Grand City Properties S.A. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Grand City Properties S.A.:
Grand City Properties S.A. engages in the residential real estate business in Germany, the United Kingdom, and internationally. The company invests in, manages, and rents real estate properties in North Rhine-Westphalia and Berlin; metropolitan regions of Dresden, Leipzig, and Halle; and the cities in the north of Germany, Bremen, Hamburg, and Hannover, as well as other urban centers, such as Nuremberg, Munch, Mannheim, Frankfurt, and London. Grand City Properties S.A. was founded in 2004 and is based in Luxembourg.
The Vonovia SE stock price gained 0.302% on the last trading day (Friday, 28th Jun 2024), rising from 26.47€ to 26.55€. During the last trading day the stock fluctuated 1.63% from a day low at 26.41€ to a day high of 26.84€. The price has been going up and down for this period, and there has been a -1.59% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 157 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately 64.31€ million.
Vonovia SE holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Vonovia SE:
Vonovia SE operates as an integrated residential real estate company in Europe. It operates through five segments: Rental, Value-Add, Recurring Sales, Development, and Deutsche Wohnen. The company offers property management services; apartments and property-related services; and value-added services, including maintenance and modernization of properties, craftsmen and residential environment organization, residential environment organization, condominium administration, cable TV, metering, energy supply, and insurances services. It also engages in the sale of individual condominiums and single-family houses; and project development activities. As of December 31, 2021, the company had 565,334 residential units; 168,015 garages and parking spaces; and 9,289 commercial units, as well as managed 71,173 residential units for other owners in Germany, Austria, and Sweden. The company was formerly known as Deutsche Annington Immobilien SE and changed its name to Vonovia SE in August 2015. Vonovia SE was founded in 1998 and is headquartered in Bochum, Germany.
The Commerzbank AG stock price gained 0.389% on the last trading day (Friday, 28th Jun 2024), rising from 14.13€ to 14.19€. During the last trading day the stock fluctuated 1.74% from a day low at 14.06€ to a day high of 14.31€. The price has been going up and down for this period, and there has been a 3.05% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 415 thousand more shares were traded than the day before. In total, 4 million shares were bought and sold for approximately 49.70€ million.
Commerzbank AG holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Commerzbank AG:
Commerzbank AG provides banking and capital market services to private and small business customers, multinational groups, financial service providers, and institutional clients worldwide. It operates through two segments, Private and Small-Business Customers, and Corporate Clients. The company offers accounts, commercial payments, payment enabling, clearing and custody, and other services; trade services, including documentary collection, letters of credit, guarantees, trade facilitation, supply chain financing, buyer's credit, and forfaiting services; and bilateral loans, club deals, Schuldschein instruments, syndicated loans, bonds, private placements, other debt instruments, and Islamic financing services. It also provides money market, and commodities and precious metals products; interest, currency, and liquidity management services, as well as wealth management services. The company operates approximately 790 branches. Commerzbank AG was founded in 1870 and is headquartered in Frankfurt am Main, Germany.
The Fresenius Medical Care AG & Co. KGaA stock price gained 0.112% on the last trading day (Friday, 28th Jun 2024), rising from 35.72€ to 35.76€. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 1.76% from a day low at 35.70€ to a day high of 36.33€. The price has been going up and down for this period, and there has been a -7.43% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 272 thousand more shares were traded than the day before. In total, 674 thousand shares were bought and sold for approximately 24.11€ million.
Fresenius Medical Care AG & Co. KGaA holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Fresenius Medical Care AG & Co. KGaA:
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
